Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec:29:100647.
doi: 10.1016/j.eclinm.2020.100647. Epub 2020 Nov 20.

Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations

Rahul Chaudhary  1   2 , Kevin P Bliden  1 , Rolf P Kreutz  3 , Young-Hoon Jeong  4   5 , Udaya S Tantry  1 , Jerrold H Levy  6 , Paul A Gurbel  1
Affiliations

Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations

Rahul Chaudhary et al. EClinicalMedicine. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Kreutz has received consulting fees from Haemonetics. Dr. Jeong has received honoraria for lectures from AstraZeneca, Sanofi-Aventis, Daiichi Sankyo/Lilly, Haemonetics, Otsuka, Han-mi Pharmaceuticals and Yuhan Pharmaceuticals; and research grants or support from AstraZeneca, Korean Society of Interventional Cardiology, Han-mi Pharmaceuticals, Yuhan Pharmaceuticals, Otsuka and Haemonetics. Dr. Levy reports honoraria for advisory boards from Instrumentation Labs, Merck, Octapharma, and Janssen. Dr. Gurbel reports grants and personal fees from Bayer HealthCare LLC, Otitopic Inc, Amgen, Janssen, and US WorldMeds LLC; grants from Instrumentation Laboratory, Haemonetics, Medicure Inc, Idorsia Pharmaceuticals, and Hikari Dx; personal fees from UpToDate; Dr Gurbel is a relator and expert witness in litigation involving clopidogrel; in addition, Dr. Gurbel has two patents, Detection of restenosis risk in patients and Assessment of cardiac health and thrombotic risk in a patient. Other authors report no disclosure.

References

    1. Maatman T.K., Jalali F., Feizpour C. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019. Crit Care Med. 2020;48:e783–ee90. - PMC - PubMed
    1. White R.H., Keenan C.R. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 2009;123(Suppl 4):S11–S17. - PubMed
    1. Gurbel P.A., Bliden K.P., Cohen E. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis. 2008;19:268–275. - PubMed
    1. Lev E.I., Bliden K.P., Jeong Y.H. Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc. 2014;3 - PMC - PubMed
    1. Jeong Y.H., Kevin B., Ahn J.H. Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. J Thromb Thrombolysis. 2020 Aug 27 doi: 10.1007/s11239-020-02240-2. - DOI - PubMed